Antinuclear antibodies and survival in cardiac transplant patients.
Serum from 48 patients with cardiac transplants was tested for the presence of antinuclear antibodies (ANA). Thirty-two of the sera were negative for ANA (ANA-), and 16 were positive for ANA (ANA+). Six of the ANA+ sera had a diffuse pattern, six had a peripheral pattern, three had a combined diffuse and rim pattern, and one had a diffuse and nucleolar pattern. Seven of the ANA+ sera were positive at a 1:40 titer, one at a 1:80 titer, four at a 1:160 titer, two at a 1:320 titer, and two at a 1:640 titer. Thirteen of the 32 ANA- patients have died, at intervals of one month to four years after transplantation. Fourteen of the 16 ANA+ patients have died, at intervals ranging from less than one day to four years after transplantation. The mean time period from transplantation to death was 13 +/- 15 months for the ANA+ patients: these were not statistically significantly different. However, the mean interval from transplantation to death of the ANA+ patients with an ANA titer greater than 1:40 was 0.8 +/- 0.8 months, which was significantly different from the mean survival period of the ANA+ group as a whole (P less than or equal to 0.05) and the mean survival of the ANA- group (P less than or equal to 0.005). Although the mechanism is not clear, there appears to be an association between higher titer serum ANA positivity and increased mortality in patients with cardiac transplants with significantly decreased duration of survival after transplantation.
Graham
A R
AR
Hicks
M J
MJ
Guillot
J M
JM
Gamble
S L
SL
D000293:Adolescent; D000328:Adult; D000974:Antibodies, Antinuclear / Q000032:analysis* / Q000276:immunology; D005260:Female; D006084:Graft Rejection; D016027:Heart Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D012306:Risk; D013997:Time Factors
D000974:Antibodies, Antinuclear